<DOC>
	<DOCNO>NCT00554632</DOCNO>
	<brief_summary>This study randomize , investigator-blinded , cross-over , clinic trial use twenty-four healthy woman age 18-35 . All woman receive two month birth control patch birth control pill , two month without drug , two month alternative drug . The birth control patch contain 0.75 milligram ethinyl estradiol 6 milligram norelgestromin . The birth control pill contain 35 microgram ethinyl estradiol 250 microgram norgestimate . Blood sample take treatment analyze follow lab value : D-dimer , von Willebrand factor , factor VIII , total free protein S , antithrombin , fibrinogen , C-reactive protein normalize activated protein C sensitivity ratio ( nAPCsr ) . Two thrombin generation-based assay use : α2macroglobulin-thrombin endpoint method ( α2M-IIa ) calibrate automate thrombinography ( CAT ) .</brief_summary>
	<brief_title>Birth Control Pill v Birth Control Patch Study</brief_title>
	<detailed_description>Twenty-four non-pregnant woman 18-35 year age , hormonal contraception least 2 month prior study least 3 month postpartum non-lactating , enrol study October 2003 February 2005 . The study protocol approve University Vermont Institutional Review Board , participant give write informed consent . Exclusion criterion participation personal family history venous thromboembolism coagulation disorder , pregnancy , uncontrolled hypertension , cardiovascular disease , complicate migraine headache , breast cancer , diabetes , abnormal uterine bleeding , liver disease , desire pregnancy le 6 month . This study randomize investigator-blind , cross-over clinical trial . The daily oral contraceptive contain 35 microgram ethinyl estradiol 250 microgram norgestimate ( Ortho Cylen® ) . The weekly transdermal hormonal contraceptive contain 0.75 milligram ethinyl estradiol 6.0 milligram norelgestromin ( Ortho Evra® ) . Norelgestromin active progestin metabolite orally administer norgestimate . For oral form average steady state plasma concentration ( Css ) ethinyl estradiol 49.3 picograms/milliliter norelgestromin 0.73 nanograms/milliliter transdermal form concentration 80.0 picograms/milliliter 0.888 nanograms/milliliter , respectively end second month use.17 The average weekly exposure , calculate area curve ( AUC0-168pg.h/mL ) ethinyl estradiol 55 % high transdermal oral contraceptive . The maximum ethinyl estradiol norelgestromin level ( Cmax ) 133 pg/ml 2.16 ng/ml oral form 97.4 pg/ml 1.12 ng/ml transdermal form.17 The application location patch alter Css Cmax.18 Medications supply patient research nurse complete packet return document compliance . The contraceptive fund study supply research grant University Vermont Department Obstetrics Gynecology . Prior enrollment , participant underwent physical examination include gynecologic examination . Women hormonal contraceptive recruitment give barrier contraceptive two month prior start study . Participants assign random identification number indicate sequence transdermal oral contraceptive would give . The daily oral contraceptive weekly transdermal contraceptive give typical dose three week active treatment follow one week without hormone use . Following first two month hormonal contraceptive , participate return barrier contraceptive two month washout period , receive two month alternative hormonal contraceptive . The investigator blind order contraceptive assign participant . There four phlebotomy perform subject . Blood drawn menstrual cycle day 18 21 prior study , within 4 day either last pill removal last patch , cycle day 18 21 second month washout period . Blood collect use standardize method minimal stasis vacutainer tube , immediately place ice centrifuge 4oC . Plasma serum store -70oC completion study . Laboratory assay perform batch participant 's serial sample analyze run . D-dimer , von Willebrand factor antithrombin measure use immuno-turbidometric assay STA-R analyzer ( Liatest D-Di , Liatest vWF , Liatest ATIII , Diagnostica Stago , Parsippany , NJ ) coefficient variation ( CVs ) 3.0 % , 3.85 % , 4.0-8.0 % respectively . Factor VIII determine measure clot time sample factor VIII deficient plasma ( STA-Deficient VIII ; Diagnostica Stago , Parsippany , NJ ) CV 3.5 % . Free total protein S measure immunoassay ( Asserachrom Free Total Protein S , Diagnostica Stago , Parsippany , NJ ) CVs 14.0 % 4.0 % respectively . Fibrinogen C-reactive protein measure immunonephelometry use BNII instrument ( N Antiserum Human Fibrinogen , N High Sensitivity CRP , Dade-Behring , Deerfield , IL ) CVs 2.3-4 % 2.6 % respectively . The normalized activated protein C sensitivity ratio ( nAPCsr ) measure use two thrombin generation assay . In first assay , coagulation trigger defibrinated plasma tissue factor presence absence activate protein C amount thrombin capture complex a2-macroglobulin 30 minute take measure thrombin generation use calculate nAPCsr ( nAPCsr α2M-IIa ) .14 In second assay , nAPCsr ( nAPCsr CAT ) determine measure thrombin generation presence absence activate protein C full plasma real-time fluorogenic thrombin substrate use calibrate automated thrombinography ( CAT ) .19 The CV 's nAPCsr α2M-IIa nAPCsr CAT 3.5 % 7 % , respectively . Repeated measure analyse variance correspond cross-over design incorporate baseline washout period use determine significance associate difference hormonal contraceptive treatment biomarkers test . Pre-planned contrast use test difference pre-treatment period correspond oral transdermal active treatment . Contrasts also use test change pre-treatment active treatment within treatment determine whether change parallel across two active treatment . Biomarkers non-normal distribution base residual plot log transform prior analysis . Based analysis variance result , evidence significant order effect biomarkers . Analyses perform use SAS Version 8.2 ( SAS Institute , Cary , NC ) . Statistical significance determine base a=.05</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Women age 1835 year age Not hormone least 2 month prior enrollment Must 3 month postpartum , &amp; Generally healthy . Women prior history contraindication take birth control pills History Deep Vein Thrombosis Pulmonary Embolism Known history coagulation disorder Liver disease Pregnant actively attempt pregnancy Currently breastfeed Uncontrolled hypertension Migraines ischemic change , &amp; Weight 199 lb .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Contraceptive</keyword>
	<keyword>Venous thrombosis</keyword>
	<keyword>Coagulation parameter</keyword>
</DOC>